FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios

A new FDA draft guidance lays out the agency's thinking on what constitutes a companion diagnostic, as well as Rx/Dx situations in which it would accommodate the marketing of unapproved tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.